Low dose fluocinolone acetonide implant safe in noninfectious uveitis

With relatively low incidence of ocular hypertension necessitating intervention, the 0.18-mg fluocinolone acetonide implant (FAi) appears to be a useful alternative in the therapy of noninfectious uveitis affecting the posterior segment (NIU-PS), says an article published in Ophthalmology Retina. 

In order to describe the effects of the 0.18-mg fluocinolone acetonide implant in the management of noninfectious uveitis, Amit Reddy and colleagues undertook this retrospective cohort study.

Individuals who received the 0.18-mg FAi at the University of Colorado between July 1, 2019, and August 31, 2021 for the treatment of noninfectious uveitis affecting the posterior segment Patients who did not get follow-up care for at least six months following implant implantation were excluded from the study. Age, sex, race/ethnicity, diagnosis of uveitis, past and present use of anti-inflammatory medication, use of short-acting corticosteroid injections within the previous three months prior to the 0.18-mg FAi implantation, visual acuity, intraocular pressure (IOP), grading of anterior chamber and vitreous cell, and presence of cystoid macular edema were all details taken from the patient's medical records. Any heightened inflammation requiring more anti-inflammatory treatment was referred to as a uveitis recurrence.